LSE - Delayed Quote USD

Heron Therapeutics, Inc. (0J4V.L)

2.0033

+0.0125

(+0.63%)

At close: September 27 at 5:13 PM GMT+1

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.

PR Newswire 2 days ago

HRTX
Exploring Three High Growth Tech Stocks in the United States

Over the last 7 days, the market has dropped 4.4%, yet in the last year, it is up 19%, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that align with these trends can be crucial for investors seeking robust opportunities in the United States market.

Simply Wall St. 18 days ago

HRTX

MGTX

DSP
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management

PR Newswire 24 days ago

HRTX
Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Heron Therapeutics ( NASDAQ:HRTX ) Second Quarter 2024 Results Key Financial Results Revenue: US$36.0m (up 13% from 2Q...

Simply Wall St. last month

HRTX
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

HRTX
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

HRTX
Heron Therapeutics: Q2 Earnings Snapshot

SAN DIEGO (AP) — Heron Therapeutics Inc. HRTX) on Tuesday reported a loss of $9.2 million in its second quarter. On a per-share basis, the San Diego-based company said it had a loss of 6 cents.

Associated Press Finance last month

HRTX
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates.

PR Newswire last month

HRTX
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights.

PR Newswire last month

HRTX
While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Simply Wall St. 2 months ago

HRTX
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outp

PR Newswire 2 months ago

HRTX
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know

Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

HRTX
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.

Zacks 2 months ago

INDV

ARQT

CGEN
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Zacks 2 months ago

HRTX

BVS
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.

PR Newswire 2 months ago

HRTX
With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners

Key Insights Significantly high institutional ownership implies Heron Therapeutics' stock price is sensitive to their...

Simply Wall St. 2 months ago

HRTX
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 3 months ago

IONS

HRTX
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.

Zacks 3 months ago

RNA

ARQT

MRNS
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.

Zacks 3 months ago

AZN

ARQT

HRTX
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026

Zacks 3 months ago

AMGN

ARQT

HRTX

Performance Overview

Return	0J4V.L	MSCI WORLD
YTD	+17.15%	+17.59%
1-Year	+98.35%	+31.19%
3-Year	-84.14%	+20.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Heron Therapeutics, Inc. (0J4V.L)

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Exploring Three High Growth Tech Stocks in the United States

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

Performance Overview